Influenza B/Yamagata viruses have not been detected globally since 2020 and will be removed from U.S. 2024/25 seasonal influenza vaccines. We inferred impacts of vaccination against B/Yamagata from 2016/17–2019/20 by combining B/Yamagata prevalence …
Seasonal influenza causes substantial morbidity and mortality in the United States. The U.S. Centers for Disease Control and Prevention (CDC) uses a compartmental framework to estimate the annual disease burden and burden prevented by vaccination for …
**Background**: High-dose, adjuvanted, and recombinant influenza vaccines may offer improved effectiveness among older adults compared to standard-dose, unadjuvanted, inactivated vaccines. However, the Advisory Committee on Immunization Practices …
Vaccines provide powerful tools to mitigate the enormous public health and economic costs that the ongoing SARS-CoV-2 pandemic continues to exert globally, yet vaccine distribution remains unequal among countries. To examine the potential …
In the face of vaccine dose shortages and logistical challenges, various deployment strategies are being proposed to increase population immunity levels to SARS-CoV-2. How timing of delivery of the second dose affects infection burden but also …